Skip to content
value.today

RxRevu, Inc.

🇺🇸 Denver, Colorado, USAHealth CareFounded 2013
Total raised
$19 M
3 rounds on record
Latest round
$6 M
Dec 2022
First round on record
Dec 2016
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of RxRevu, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$6 MNo. 3$2 to $10 million

RxRevu, Inc.: Raise no. 3, Dec 2022

Investors in this round

1 investor had bought by the notice of Jan 17, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $10 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aaron Cornell · Executive Officer
  • Benton Barney · Executive Officer
  • Christie Callahan · Executive Officer
  • Kyle Kiser · Executive Officer, Director
  • Lew Parker · Executive Officer
  • Steve Lindseth · Executive Officer, Director
  • Albert Prast · Director
  • Andrew Firlik · Director
  • Daniel Galles · Director
  • Richard Zane · Director
  • Stephen McHale · Director
  • Toby Cosgrove · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kyle Kiser, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 17, 2023. Read the notice at the SEC.

equitySEC
Jun 2021$8 MNo. 2$2 to $10 million

RxRevu, Inc.: Raise no. 2, Jun 2021

Investors in this round

1 investor had bought by the notice of Jul 8, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aaron Cornell · Executive Officer
  • Kyle Kiser · Executive Officer, Director
  • Steve Lindseth · Executive Officer, Director
  • Albert Prast · Director
  • Andrew Firlik · Director
  • Daniel Galles · Director
  • Richard Zane · Director
  • Stephen McHale · Director
  • Toby Cosgrove · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kyle Kiser, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 8, 2021. Read the notice at the SEC.

equitySEC
Dec 2016$5 MNo. 1$2 to $10 million

RxRevu, Inc.: Raise no. 1, Dec 2016

Investors in this round

44 investors had bought by the notice of Jan 6, 2017: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Carmody Caron · Executive Officer
  • David Carmody Huntress · Executive Officer, Director
  • Kevin Carmody O'Brien · Executive Officer, Director
  • Jeffrey Carmody Patton · Director
  • Steve Carmody Lindseth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amount sold includes the conversion of outstanding convertible indebtedness.”

Signed by David Carmody Huntress, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 6, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • RxRevu, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2023).

    SEC Form D · Jan 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jan 2023

That is all the official record says: RxRevu, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of RxRevu, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 44 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by RxRevu, Inc.
NameRoleNamed in
Aaron CornellExecutive officerJan 2023
Benton BarneyExecutive officerJan 2023
Christie CallahanExecutive officerJan 2023
Kyle KiserExecutive officerJan 2023
Lew ParkerExecutive officerJan 2023
Steve LindsethExecutive officerJan 2023
Daniel Carmody CaronExecutive officerJan 2017
David Carmody HuntressExecutive officerJan 2017
Kevin Carmody O'BrienExecutive officerJan 2017
Albert PrastDirectorJan 2023
Andrew FirlikDirectorJan 2023
Daniel GallesDirectorJan 2023
Kyle KiserDirectorJan 2023
Richard ZaneDirectorJan 2023
Stephen McHaleDirectorJan 2023
Steve LindsethDirectorJan 2023
Toby CosgroveDirectorJan 2023
David Carmody HuntressDirectorJan 2017
Jeffrey Carmody PattonDirectorJan 2017
Kevin Carmody O'BrienDirectorJan 2017
Steve Carmody LindsethDirectorJan 2017